Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines.

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...

The clinical trial that Eli Lilly terminated was expected to enroll 180 people and finish in late 2026. The trial had been measuring how well Bimagrumab stimulates weight loss and preserves muscle ...

The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency’s concerns and now sees potential for a speedy review.

Capricor Therapeutics has been performing a balancing act with its lead drug for more than a year. After the cell therapy posted positive mid-stage data in May 2020 for the rare disease Duchenne ...

Avidity's del-zota treatment improved muscle function, increased dystrophin levels, and reduced damage markers in Duchenne muscular dystrophy after one year.

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...